ofloxacin has been researched along with Kidney Failure, Chronic in 32 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The administration of levofloxacin to patients with ESRD as 500 mg initially, followed by 250 mg every 48 hours, will provide adequate C(max)-MIC ratios after the first and subsequent doses for most patients with respiratory tract infections caused by organisms with levofloxacin MICs of 1 microg/mL or less." | 3.72 | Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ( Hamburger, RJ; Kays, MB; Lucksiri, A; Mueller, BA; Scott, MK; Sowinski, KM, 2003) |
| " The proposed dosing regimen could be an adequate therapy of peritonitis and exit-site infections in patients on CAPD since levels reached in the dialysate effluent are bactericidal." | 2.66 | Single- and multiple-dose kinetics of ofloxacin in patients on continuous ambulatory peritoneal dialysis (CAPD). ( Essers, L; Grabensee, B; Keller, E; Passlick, J; Wonner, R, 1989) |
| " The purpose of this paper is to review the concepts pertinent to drug removal by hemodialysis and discuss the issues related to these new dialysis techniques and how they may have a impact on drug removal and the design of dosing regimens." | 2.44 | Drug dosing considerations in alternative hemodialysis. ( Decker, BS; Mueller, BA; Sowinski, KM, 2007) |
| "Fluoroquinolones present various pharmacokinetic properties." | 2.42 | [Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis]. ( Christmann, D; Daniel, JP; Moulin, B, 2004) |
| " Consequently, the serum half-life progressively increases when creatinine clearance decreases." | 2.38 | Ofloxacin pharmacokinetics in chronic renal failure and dialysis. ( Lameire, N; Lehr, KH; Malerczyk, V; Ringoir, S; Rosenkranz, B; Veys, N, 1991) |
| " For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment." | 2.38 | Pharmacokinetics of quinolones in renal insufficiency. ( Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990) |
| "A 55 year-old male patient with chronic renal failure was hospitalized in intensive care unit following cardiopulmonary arrest." | 1.38 | [A case of ventilator-associated pneumonia due to Pantoea agglomerans]. ( Altın, N; Argun, C; Canbakan, B; Cesur, S; Koldaş, K; Kurşun, O; Sencan, I; Unal, N, 2012) |
| " Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5." | 1.35 | Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ( Digenis, P; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Kouki, P; Tsaganos, T, 2008) |
| "Levofloxacin is a fluoroquinolone antibiotic commonly used to treat respiratory, urinary tract, skin and soft-tissue infections." | 1.32 | Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient. ( Lee, CH; Schwalm, JD, 2003) |
| " The half-life was 4." | 1.30 | Ofloxacin clearance during hemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers. ( Burgmann, H; El Menyawi, I; Hörl, WH; Kletzmayr, J; Kovarik, J; Rosenkranz, AR; Thalhammer, F; Traunmüller, F, 1998) |
| " It is concluded that in patients on regular haemodialysis treatment the dosage adjustment employed resulted in safe and therapeutically favourable plasma concentrations." | 1.28 | Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients. ( Borner, K; Kampf, D; Pustelnik, A, 1992) |
| " every 6 h for one day only, while 4 patients with acute peritonitis were treated with this same dosage every 4 h for 3 days, then every 6 h for the next 7 days." | 1.28 | Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients. ( Borner, K; Conrad, W; Hain, H; Kampf, D, 1991) |
| " Apparent total body and renal clearances declined and elimination half-life increased with decreasing creatinine clearance." | 1.28 | Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment. ( Flor, S; Guay, D; Matzke, G; Opsahl, J; Tack, K, 1991) |
| " At a Tmax of 1." | 1.28 | Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis. ( Borner, K; Kampf, D; Pustelnik, A, 1990) |
| " On the basis of these results, a means of determining suitable dosage reduction factors in patients with renal impairment is presented." | 1.27 | Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function. ( Höffler, D; Koeppe, P, 1987) |
| " These results confirm that dosage reduction of ofloxacin is required in haemodialysis patients." | 1.27 | The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. ( MacGowan, AP; Mackay, IG; Reeves, DS; White, LO, 1988) |
| "Treatment with ofloxacin in 15 patients with chronic renal failure at different stages is reported with respect to patients undergoing hemodialysis treatment." | 1.27 | [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results]. ( Dörfler, A; Schulz, W, 1986) |
| " The pharmacokinetic parameters were obtained using an open one-compartment model." | 1.27 | Pharmacokinetics of a single oral dose of ofloxacin in patients with renal failure. ( Moukhtar, I; Nawishy, S; Sabbour, M, 1986) |
| " An open three-compartment body model was used to calculate ofloxacin pharmacokinetic parameters." | 1.27 | Ofloxacin pharmacokinetics in renal failure. ( Fillastre, JP; Humbert, G; Leroy, A, 1987) |
| " In 2 patients with chronic renal failure, specific HPLC assay indicated an extended half-life for ofloxacin (approximately 13 hours) and the appearance in serum of low concentrations of both metabolites after 10 hours, persisting until the last blood sample was taken (32 hours)." | 1.27 | A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure. ( Lovering, AM; MacGowan, AP; Mackay, IG; Reeves, DS; White, LO, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (28.13) | 18.7374 |
| 1990's | 9 (28.13) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 6 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Humar, A | 1 |
| Gill, J | 1 |
| Johnston, O | 1 |
| Fergusson, D | 1 |
| House, AA | 1 |
| Lebel, L | 1 |
| Cockfield, S | 1 |
| Kim, SJ | 1 |
| Zaltzman, J | 1 |
| Cantarovich, M | 1 |
| Karpinski, M | 1 |
| Ramsay, T | 1 |
| Knoll, GA | 1 |
| Tsaganos, T | 1 |
| Kouki, P | 1 |
| Digenis, P | 1 |
| Giamarellou, H | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Kanellakopoulou, K | 1 |
| Bhagan-Bruno, S | 1 |
| Lather, N | 1 |
| Fergus, IV | 1 |
| Kato, A | 1 |
| Ishigaki, S | 1 |
| Yasuda, H | 1 |
| Kurşun, O | 1 |
| Unal, N | 1 |
| Cesur, S | 1 |
| Altın, N | 1 |
| Canbakan, B | 1 |
| Argun, C | 1 |
| Koldaş, K | 1 |
| Sencan, I | 1 |
| Parra-Riffo, H | 1 |
| Lemus-Peñaloza, J | 1 |
| Takeda, S | 1 |
| Imai, T | 1 |
| Chaki, Y | 1 |
| Kusano, E | 1 |
| Schwalm, JD | 1 |
| Lee, CH | 1 |
| Bibb, JL | 1 |
| Servilla, KS | 1 |
| Gibel, LJ | 1 |
| Kinne, JE | 1 |
| White, RE | 1 |
| Hartshsorne, MF | 1 |
| Tzamaloukas, AH | 1 |
| Sowinski, KM | 2 |
| Lucksiri, A | 1 |
| Kays, MB | 1 |
| Scott, MK | 1 |
| Mueller, BA | 2 |
| Hamburger, RJ | 1 |
| Airey, K | 1 |
| Koller, E | 1 |
| Daniel, JP | 1 |
| Moulin, B | 2 |
| Christmann, D | 1 |
| Patel, MC | 1 |
| Levi, MH | 1 |
| Mahadevi, P | 1 |
| Nana, M | 1 |
| Merav, AD | 1 |
| Robbins, N | 1 |
| Decker, BS | 1 |
| Tsubakihara, Y | 2 |
| Hayashi, T | 1 |
| Shoji, T | 1 |
| Kitamura, E | 1 |
| Okada, N | 2 |
| Nakanishi, I | 2 |
| Thalhammer, F | 1 |
| Kletzmayr, J | 1 |
| El Menyawi, I | 1 |
| Kovarik, J | 1 |
| Rosenkranz, AR | 1 |
| Traunmüller, F | 1 |
| Hörl, WH | 1 |
| Burgmann, H | 1 |
| Bagon, JA | 1 |
| Kampf, D | 3 |
| Borner, K | 3 |
| Pustelnik, A | 2 |
| Hain, H | 1 |
| Conrad, W | 1 |
| Lameire, N | 1 |
| Rosenkranz, B | 1 |
| Malerczyk, V | 1 |
| Lehr, KH | 1 |
| Veys, N | 1 |
| Ringoir, S | 1 |
| Flor, S | 1 |
| Guay, D | 1 |
| Opsahl, J | 1 |
| Tack, K | 1 |
| Matzke, G | 1 |
| Fillastre, JP | 2 |
| Leroy, A | 3 |
| Dhib, M | 1 |
| Borsa-Lebas, F | 1 |
| Humbert, G | 3 |
| Passlick, J | 1 |
| Wonner, R | 1 |
| Keller, E | 1 |
| Essers, L | 1 |
| Grabensee, B | 1 |
| Höffler, D | 1 |
| Koeppe, P | 1 |
| White, LO | 2 |
| MacGowan, AP | 2 |
| Mackay, IG | 2 |
| Reeves, DS | 2 |
| Schulz, W | 1 |
| Dörfler, A | 1 |
| Nawishy, S | 1 |
| Moukhtar, I | 1 |
| Sabbour, M | 1 |
| Lovering, AM | 1 |
| Bandai, H | 1 |
| Yamato, E | 1 |
| Yokoyama, K | 1 |
| Iida, N | 1 |
| Couet, W | 1 |
| Mignot, A | 1 |
| Lefebvre, M | 1 |
| Akbaraly, J | 1 |
| Fourtilan, J | 1 |
| Fillastre, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study[NCT01353339] | Phase 4 | 154 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for ofloxacin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Severe levofloxacin-induced hypoglycaemia: a case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Catheter-Related Infections; Drug Therapy, Combination; Enterococcus; G | 2012 |
[Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Kidney Failure, Chronic; Ofloxacin; | 2004 |
L. micdadei PVE successfully treated with levofloxacin/valve replacement: case report and review of the literature.
Topics: Anti-Bacterial Agents; Bioprosthesis; Device Removal; Endocarditis, Bacterial; Heart Valve Prosthesi | 2005 |
Drug dosing considerations in alternative hemodialysis.
Topics: Anti-Infective Agents, Urinary; Blood Urea Nitrogen; Dose-Response Relationship, Drug; Drug Administ | 2007 |
Ofloxacin pharmacokinetics in chronic renal failure and dialysis.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Creatinine; Humans; Injections, Intraven | 1991 |
Pharmacokinetics of quinolones in renal insufficiency.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Glomerular Filtration | 1990 |
2 trials available for ofloxacin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Canada; Clinical Protocols; Double-Blind Me | 2013 |
Single- and multiple-dose kinetics of ofloxacin in patients on continuous ambulatory peritoneal dialysis (CAPD).
Topics: Administration, Oral; Adult; Dialysis Solutions; Drug Administration Schedule; Drug Evaluation; Fema | 1989 |
24 other studies available for ofloxacin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Blood Chemical Analysis; Chromatography, High P | 2008 |
Acinetobacter endocarditis presenting as a large right atrial mass: an atypical presentation.
Topics: Acinetobacter Infections; Adult; Anti-Bacterial Agents; Catheters, Indwelling; Cefepime; Cephalospor | 2010 |
Levofloxacin-associated Achilles tendinitis in a patient with chronic kidney disease stage 5.
Topics: Achilles Tendon; Bronchitis; Female; Humans; Kidney Failure, Chronic; Levofloxacin; Magnetic Resonan | 2011 |
[A case of ventilator-associated pneumonia due to Pantoea agglomerans].
Topics: Anti-Bacterial Agents; Cefoperazone; Cross Infection; Drug Therapy, Combination; Enterobacteriaceae | 2012 |
Four consecutive cases of Achilles tendon disorders associated with levofloxacin treatment in hemodialysis patients.
Topics: Achilles Tendon; Administration, Oral; Aged; Anti-Infective Agents, Urinary; Dose-Response Relations | 2012 |
Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient.
Topics: Acute Disease; Aged; Anti-Infective Agents; Cellulitis; Chemical and Drug Induced Liver Injury; Huma | 2003 |
Pyocystis in patients on chronic dialysis. A potentially misdiagnosed syndrome.
Topics: Aged; Anti-Infective Agents; Diagnostic Errors; Diverticulitis; Female; Humans; Kidney Failure, Chro | 2002 |
Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Cellulose; Chromatography, High Pressure Liquid; Femal | 2003 |
Acute hepatitis associated with levofloxacin in a patient with renal insufficiency.
Topics: Acute Disease; Alkaline Phosphatase; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; | 2003 |
[Pharmacokinetic study of ofloxacin using saliva concentration in chronic renal failure].
Topics: Adolescent; Adult; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oflo | 1994 |
Ofloxacin clearance during hemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Biocompatible Materials; Cellulose; Humans; K | 1998 |
Neuropsychiatric complications following quinolone overdose in renal failure.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Confusion; Drug Over | 1999 |
Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.
Topics: Adult; Aged; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ofloxacin; Renal Dialysis | 1992 |
Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients.
Topics: Acute Disease; Aged; Dialysis Solutions; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 1991 |
Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
Topics: Administration, Oral; Adult; Creatinine; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; M | 1991 |
Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis.
Topics: Adult; Aged; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Mid | 1990 |
Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function.
Topics: Adult; Anti-Bacterial Agents; Bacillus subtilis; Humans; Kidney Failure, Chronic; Middle Aged; Oflox | 1987 |
The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chromatography, High Pressure Liquid; Female; Fluoro | 1988 |
[Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results].
Topics: Adult; Aged; Aluminum Hydroxide; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections; Cre | 1986 |
Pharmacokinetics of a single oral dose of ofloxacin in patients with renal failure.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Half-Life; Humans; Kidney Failure, C | 1986 |
Ofloxacin pharmacokinetics in renal failure.
Topics: Adult; Aged; Anti-Infective Agents; Creatinine; Glomerular Filtration Rate; Half-Life; Humans; Kidne | 1987 |
A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Kidney Failur | 1987 |
[Pharmacokinetics of ofloxacin in patients with severe renal impairment].
Topics: Humans; Kidney Failure, Chronic; Metabolic Clearance Rate; Ofloxacin; Oxazines; Renal Dialysis | 1987 |
Ofloxacin pharmacokinetics in renal failure.
Topics: Chromatography, High Pressure Liquid; Half-Life; Humans; Kidney Failure, Chronic; Metabolic Clearanc | 1987 |